POS1160 A PHASE IB, MULTICENTRE, OPEN-LABEL, DOSE-ESCALATION STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUSLY ADMINISTERED MOSUNETUZUMAB IN PARTICIPANTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

医学 药代动力学 药效学 耐受性 药理学 不利影响 麻醉
作者
Vishala Chindalore,Edésio Martins,William F. Pendergraft,Xiao-gang Sheng,Anne Schroeder,L. Gearhart,Hardik Mody,Huiyan Mao,Jay Garg,Ibrahim Fares,S. Agachi
出处
期刊:Annals of the Rheumatic Diseases [BMJ]
卷期号:84: 1232-1233 被引量:7
标识
DOI:10.1016/j.ard.2025.06.510
摘要

Background: Systemic lupus erythematosus (SLE) is an autoimmune disease primarily affecting young women of childbearing age. Autoreactive B cells are central to the pathogenesis of SLE, and variability in B-cell depletion with type I anti-CD20 antibodies in SLE may be responsible for inconsistent clinical responses. Mosunetuzumab is a humanised IgG1 CD20xCD3 bispecific antibody approved for refractory follicular lymphoma that engages and redirects T cells to kill B cells. Due to its mechanism of action, mosunetuzumab treatment may provide an alternative means to manage B-cell populations in blood and tissues of patients with autoimmune diseases, such as SLE. Objectives: To determine the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics of subcutaneously (SC) administered mosunetuzumab in participants with SLE. Methods: This Phase Ib, multicentre, open-label, dose-escalation study (NCT05155345) enrolled 15 adult participants diagnosed with active autoantibody positive SLE demonstrated by a Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) total score ≥4 at screening. The study design included two non-fractionated/dose-finding cohorts and three fractionated/dose-escalation cohorts (Figure 1). To assess severe and unexpected acute drug or injection-related toxicities, a dose-limiting toxicity (DLT) assessment period of 21 days in non-fractionated/dose-finding cohorts and 28 days (21 days after Day 8) in fractionated/dose-escalation cohorts was instituted. All participants were followed for safety for at least 12 months from the last mosunetuzumab dose. Clinical and laboratory assessments, including SLEDAI-2K scores, were also conducted at study visits. Peripheral CD19+ B-cell counts were analysed using high-sensitivity flow cytometry (lower limit of quantification: 0.441 cells/µL). T-cell phenotyping was performed using conventional flow cytometry. Results: Mosunetuzumab dosing occurred in 15 patients. During the DLT assessment period, no DLTs and no serious adverse events occurred in any cohorts. Four of 15 patients experienced a total of 5 cytokine release syndrome (CRS) events; all were Grade 1-2 and none required tocilizumab administration. During the DLT assessment period, non-serious Grade 1-2 infections occurred in 5 of 15 patients, and no neutropenia or other unexpected high-grade laboratory abnormalities occurred. One patient receiving concomitant acenocoumarol experienced a transient increase in international normalised ratio due to expected cytochrome P450 inhibition by transient cytokine release, requiring acenocoumarol dose adjustment. No high-grade CRS and no immune effector cell-associated neurotoxicity syndrome occurred. One study participant in the 5/45 mg cohort died from interstitial pneumonia 37 days after the end of the DLT assessment period, and the death was deemed unrelated to mosunetuzumab by the investigator and the Sponsor. Four of 6 patients with baseline SLEDAI-2K ≥8 points had a decrease ≥4 points; 3 of 4 patients with positive anti-double-stranded DNA had a decrease in antibody levels. The PK profile of mosunetuzumab SC in patients with SLE appeared consistent with that previously observed for relapsed or refractory Non-Hodgkin lymphoma (NHL) and largely exhibited a dose-dependent increase in exposures. Mosunetuzumab depleted peripheral B cells in patients with SLE (≤0.441 cells/µL) in a dose-dependent manner (Figure 2). Mosunetuzumab-driven T-cell activation revealed that both CD4+ and CD8+ T cells were activated in all tested doses. Conclusion: Preliminary data from this Phase Ib study indicated that mosunetuzumab exhibits an acceptable safety profile in patients with SLE and that its PK profile in the SLE population is closely aligned with that observed in the relapsed or refractory NHL population. Deep B-cell depletion in the higher-dose cohorts demonstrated the potential for treating B-cell–driven autoimmune diseases. Whilst this study was designed to evaluate the safety and PK profile of mosunetuzumab with a limited dosing regimen, there did appear to be a positive impact on clinical activity. Future clinical studies are required to further evaluate and characterise the efficacy and safety of mosunetuzumab in patients with SLE and other B-cell–driven autoimmune diseases. REFERENCES: NIL . Acknowledgements: Funded by F. Hoffmann-La Roche Ltd. Editorial assistance was provided by Nucleus Global, an Inizio company, and funded by F. Hoffmann-La Roche Ltd. Disclosure of Interests: Vishala Chindalore received research support from F. Hoffman-La Roche Ltd, Elsa Martins employee of F. Hoffmann-La Roche Ltd., William F. Pendergraft III shareholder of F. Hoffmann-La Roche Ltd, employee of Genentech, Inc., X. Rebecca Sheng shareholder of F. Hoffmann-La Roche Ltd., employee of Genentech, Inc., Aaron Schroeder shareholder of F. Hoffmann-La Roche Ltd, employee of Genentech, Inc., Liudmila Gearhart employee of F. Hoffmann-La Roche Ltd, Hardik Mody shareholder of F. Hoffmann-La Roche Ltd., employee of Genentech, Inc., Huiyan (Ashley) Mao shareholder of F. Hoffmann-La Roche Ltd., employee of Hoffmann-La Roche Ltd., Jay Garg shareholder of F. Hoffmann-La Roche Ltd, employee of Genentech, Inc., Iwona Dankiewicz Fares: None declared, Svetlana Agachi received research support from F. Hoffman-La Roche Ltd. © The Authors 2025. This abstract is an open access article published in Annals of Rheumatic Diseases under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). Neither EULAR nor the publisher make any representation as to the accuracy of the content. The authors are solely responsible for the content in their abstract including accuracy of the facts, statements, results, conclusion, citing resources etc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
past完成签到 ,获得积分10
1秒前
Essie完成签到,获得积分10
1秒前
2秒前
okk发布了新的文献求助10
2秒前
2秒前
3秒前
路口发布了新的文献求助10
4秒前
郭佳杰发布了新的文献求助10
4秒前
4秒前
syalonyui完成签到,获得积分10
5秒前
5秒前
摆烂ing发布了新的文献求助10
5秒前
5秒前
FashionBoy的应助被myf采纳,获得10
5秒前
风继续吹发布了新的文献求助10
5秒前
yzystas发布了新的文献求助20
7秒前
深情安青的应助被和谐如风采纳,获得10
8秒前
9秒前
9秒前
9秒前
9秒前
10秒前
11秒前
开朗紫发布了新的文献求助10
11秒前
LICHT完成签到,获得积分10
11秒前
荒野到海边完成签到,获得积分10
12秒前
爱在日月明完成签到,获得积分20
12秒前
大模型的应助被路口采纳,获得10
12秒前
changlanya完成签到,获得积分10
12秒前
bkagyin的应助被无辜的醉波采纳,获得10
13秒前
小白飞526完成签到,获得积分10
13秒前
俏皮的三毒完成签到 ,获得积分10
13秒前
13秒前
14秒前
顾淮眠完成签到,获得积分10
14秒前
xie完成签到 ,获得积分20
15秒前
张张完成签到,获得积分20
15秒前
朴素海亦发布了新的文献求助30
15秒前
16秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
Boundaries and Bodhisattvas 500
高分子基功能界面水蒸发材料与应用研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8181408
求助须知:如何正确求助?哪些是违规求助? 9571330
关于积分的说明 21817615
捐赠科研通 7777856
什么是DOI,文献DOI怎么找? 3433479
关于科研通互助平台的介绍 2557696
邀请新用户注册赠送积分活动 2479527